Dimension Therapeutics, a life sciences startup partnered with Pennsylvania University, raises $65m in series B.

US-based life sciences firm Dimension Therapeutics has raised $65m in its series B to advance development of its gene therapy treatments for rare diseases with a focus on the liver.

New Leaf Venture Partners led the round, and was joined by fellow new investors Jennison Associates, Partner Fund Management, RA Capital Management, Rock Springs Capital, and Tourbillon Global Ventures, as well as existing investors Fidelity Biosciences and OrbiMed.

Dimension has now raised $124.5m through its series B, a $24.5m private…